Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1 + cell lines

Cytokine

Volumn 56, Issue 2, 2011, Pages 231-238

  Chen, Yongjing ^a,b   Wang, Qin ^a,b   Shi, Bimin ^c   Xu, Ping ^b   Hu, Zhenhua ^b   Bai, Lixiong ^a   Zhang, Xueguang ^a,b  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

ELISA; Expression; PD L1; Soluble

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; MYELOMA CELL; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; SERUM; SUPERNATANT;

AGE FACTORS; ANIMALS; ANTIGENS, CD274; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIMIT OF DETECTION; MATRIX METALLOPROTEINASE 1; MICE; MICE, INBRED BALB C; REPRODUCIBILITY OF RESULTS; TUMOR ESCAPE;

EID: 80053305855     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.06.004     Document Type: Article

References (38)

1. Marelli-Berg F.M., Okkenhaug K., Mirenda V. A two-signal model for T cell trafficking. Trends Immunol 2007, 28:267-273.
2. Watts T.H. TNF/TNFR family members in co-stimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
3. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
4. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895.
5. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
6. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
7. Youngnak P., Kozono Y., Kozono H., Iwai H., Otsuki N., Jin H., et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003, 307:672-677.
8. Liang S.C., Greenwald R.J., Latchman Y.E., Rosas L., Satoskar A., Freeman G.J., et al. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol 2006, 36:58-64.
9. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002, 169:5538-5545.
10. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
11. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immuno inhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
12. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G.J., Minato N., et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 2002, 84:57-62.
13. Mazanet M.M., Hughes C.C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002, 169:3581-3588.
14. Eppihimer M.J., Gunn J., Freeman G.J., Greenfield E.A., Chernova T., Erickson J., et al. Expression and regulation of the PD-L1 immuno-inhibitory molecule on microvascular endothelial cells. Microcirculation 2002, 9:133-145.
15. Lee J., Zhuang Y., Wei X., Shang F., Wang J., Zhang Y., et al. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 2009, 46:169-176.
16. Lee S.J., Jang B.C., Lee S.W., Yang Y.I., Suh S.I., Park Y.M., et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006, 580:755-762.
17. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006, 203:883-895.
18. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
19. Keir M.E., Latchman Y.E., Freeman G.J., Sharpe A.H. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 2005, 175:7372-7379.
20. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002, 99:12293-12297.
21. Okazaki T., Wang J. PD-1/PD-L pathway and autoimmunity. Autoimmunity 2005, 38:353-357.
22. del Rio M.L., Buhler L., Gibbons C., Tian J., Rodriguez-Barbosa J.I. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transpl Int 2008, 21:1015-1028.
23. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
24. Viallard J.F., Solanilla A., Gauthier B., Contin C., Déchanet J., Grosset C., et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002, 99:2612-2614.
25. Wang Q., Chen Y., Xie F., Ge Y., Chen L., Wu H., et al. Development of a sandwich ELISA for evaluating soluble OX40L (CD252) in human sera of different ages or with Graves' disease. Cytokine 2006, 36:23-28.
26. Jung H.W., Choi S.W., Choi J.I., Kwon B.S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2003, 36:13-22.
27. Jeannin P., Magistrelli G., Aubry J.P., Caron G., Gauchat J.F., Renno T., et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000, 13:303-312.
28. Her M., Kim D., Oh M., Jeong H., Choi I. Increased expression of soluble inducible co-stimulator ligand (ICOSL) in patients with systemic lupus erythematosus. Lupus 2009, 18:501-507.
29. Oaks M.K., Hallett K.M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000, 164:5015-5018.
30. Simon I., Zhuo S., Corral L., Diamandis E.P., Sarno M.J., Wolfert R.L., et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006, 66:1570-1575.
31. Sun J., Xu K., Wu C., Wang Y., Hu Y., Zhu Y., et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 2007, 69:19-27.
32. Findlay J.W., Dillard R.F. Appropriate calibration curve fitting in ligand binding assays. AAPS J 2007, 9:E260-E267.
33. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 co-receptor expression and signal transduction. Immunol Rev 2009, 229:12-26.
34. Dotti G. Blocking PD-1 in cancer immunotherapy. Blood 2009, 114:1457-1458.
35. Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009, 22:1041-1050.
36. Hikita A., Tanaka N., Yamane S., Ikeda Y., Furukawa H., Tohma S., et al. Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha. Biochem Cell Biol 2009, 87:581-593.
37. Zhang G., Hou J., Shi J., Yu G., Lu B., Zhang X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 2008, 123:538-546.
38. He X.H., Xu L.H., Liu Y. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin 2005, 26:462-468.